January 1, BREAKTHROUGH Blood Test Catches Deadly Cancer MSM Won’t Tell You About

Wyatt’s Take

• New blood test catches 90% of aggressive prostate cancer — blows away the old standard that’s been failing American men since the 1990s
• The outdated PSA test misses dangerous cases while sending healthy men through costly, invasive procedures — medical establishment dragged its feet for decades
• When caught early, survival rate is nearly 100% — but cases of advanced disease are rising because current screening isn’t doing its job

A new blood test is making the medical establishment look foolish, catching deadly prostate cancer cases that the current standard screening completely misses.

The Stockholm3 blood test detected 90% of aggressive prostate cancer cases in a major study, while the PSA test that doctors have been using since the 1990s only caught 74%. That’s a massive gap when lives are on the line.

Researchers from Sweden’s Karolinska Institutet studied more than 12,000 men aged 50 to 74, following them for two years. During that time, 443 men were diagnosed with aggressive prostate cancer — the kind that kills if you don’t catch it early.

Stockholm3 missed “significantly fewer” serious cancer cases than the PSA test. And here’s the kicker — it didn’t increase false alarms that send men through unnecessary hell.

Thorgerdur Palsdottir, a researcher at Karolinska Institutet, said one of the biggest challenges is identifying cases that are “truly dangerous.”

“Our results show that Stockholm3 identifies significantly more aggressive cancer cases than PSA, without increasing the number of unnecessary follow-ups.”

“These results point toward a potential change in how prostate cancer screening can be conducted. A more precise blood test could enable earlier detection of aggressive disease while reducing the number of unnecessary follow-up examinations and procedures.”

Dr. Hari Vigneswaran, chief medical officer of Stockholm3-maker A3P Biomedical, told reporters the PSA test has “well-documented limitations” that the medical community has ignored for thirty years.

“It leads to invasive and costly follow-up testing, contributes to over-diagnosis of non-aggressive cancers and, most importantly, it misses a substantial share of aggressive disease.”

When aggressive prostate cancer is caught while still confined to the prostate, the five-year survival rate is close to 100%. But here’s the problem — cases of metastatic prostate cancer have been rising over the past decade.

“We have not improved early detection of the aggressive, curable disease that screening is meant to catch,” Vigneswaran said.

“The goal of screening is to find the cancers that need treatment while they are still curable, without raising the number of men who screen positive but don’t have aggressive disease.”

Stockholm3 could slash the need for unnecessary MRIs and biopsies that cost patients thousands and put them through invasive procedures they never needed in the first place.

The test isn’t available for sale in the U.S. yet. The company plans to seek FDA approval for routine screening, but you know how slow that process moves — especially when it threatens established medical practices.

While Stockholm3 estimates a man’s risk of aggressive prostate cancer, a biopsy is still needed to confirm the disease. But catching the right men earlier could save countless lives.

Wyatt Matters

American men have been failed by a broken screening system for three decades while the medical establishment stuck with outdated tests. Working men don’t have time or money for unnecessary procedures that bankrupt families, and they sure can’t afford to have deadly cancer missed because the “experts” were too stubborn to demand better. When a simple blood test can catch 90% of killers versus 74%, and our fathers and brothers are dying from cancers that slipped through, it’s time to ask who’s really looking out for regular Americans.